Parameter
| Biomarker | CA19-9 (carbohydrate antigen 19-9) | Full name | Carbohydrate antigen 19-9 | Molecular Type | Protein |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Diagnosis, prognosis, and monitoring | ||
| Disease | Gastric Cancer | Disease Subtypes | / | ||
| Organ | Stomach | Test Sample / Technology Platform | Serum (ELISA, chemiluminescence immunoassay), tumor tissue (IHC) | ||
| Pathobiological Mechanisms | Glucolipid antigens on the surface of cell membrane are secreted by pancreatic and gastrointestinal epithelial cells, and abnormally synthesized by gastric cancer cells, leading to elevated serum levels. They promote tumor proliferation, invasion and chemoresistance by participating in cell signal transduction. High expression of glucolipid antigens indicates strong invasion and poor prognosis | ||||
| Clinical Availability Status | Clinical usefulness (auxiliary diagnosis/prognosis evaluation) : the positive rate of routine clinical detection items in advanced gastric cancer (18%-44%) is higher than that in the early stage, and the sensitivity of liver metastasis monitoring is higher | ||||
| Notes and Dynamics | The diagnostic specificity of CEA for gastric cancer (85%-95%) is higher than that of CEA, but about 5%-10% of patients are false negative due to negative Lewis antigen. The combination of CEA and CA72-4 can reduce missed diagnosis and is one of the core indicators for the monitoring of advanced gastric cancer | ||||